Document is current

Any future updates will be listed below

271 Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.271

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark